GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » Notes Receivable

CARsgen Therapeutics Holdings (HKSE:02171) Notes Receivable : HK$0.00 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is CARsgen Therapeutics Holdings Notes Receivable?

CARsgen Therapeutics Holdings's Notes Receivable for the quarter that ended in Jun. 2024 was HK$0.00 Mil.


CARsgen Therapeutics Holdings Notes Receivable Historical Data

The historical data trend for CARsgen Therapeutics Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARsgen Therapeutics Holdings Notes Receivable Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
- - - - -

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CARsgen Therapeutics Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


CARsgen Therapeutics Holdings Notes Receivable Related Terms

Thank you for viewing the detailed overview of CARsgen Therapeutics Holdings's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


CARsgen Therapeutics Holdings Business Description

Traded in Other Exchanges
N/A
Address
No. 466 Yindu Road, Building 2, 1st Floor, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America.
Executives
Guo Bingsen 2401 A concert party to an agreement to buy shares
Guo Huaqing 2101 Beneficial owner
Li Zonghai 2401 A concert party to an agreement to buy shares
Wang Huamao 2401 A concert party to an agreement to buy shares
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Private Limited 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Yang Zhi 2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd 2201 Interest of corporation controlled by you
Bvcf Realization Fund, L.p. 2201 Interest of corporation controlled by you
Bvcf Realization Fund Gp, Ltd. 2201 Interest of corporation controlled by you
Zhejiang Jolly Healthcare Investment Management Limited 2201 Interest of corporation controlled by you
Applied Biomaterial Ltd. 2201 Interest of corporation controlled by you
Zhejiang Jolly Pharmaceutical Co., Ltd. 2201 Interest of corporation controlled by you
Zhejiang Zuoli Innovation Medical Investment Management Co., Ltd. 2101 Beneficial owner

CARsgen Therapeutics Holdings Headlines

No Headlines